Roche promises $1B to China biotech for preclinical COPD bispecificnews2025-10-30T01:48:30+00:00October 30th, 2025|Endpoints News|
BIO chief to senators: China could pass US within two yearsnews2025-10-29T18:51:36+00:00October 29th, 2025|Endpoints News|
WuXi AppTec to divest clinical services to focus on manufacturing businessnews2025-10-27T13:42:32+00:00October 27th, 2025|Endpoints News|
Starna Therapeutics raises $44M to advance in vivo CAR-T programs after early clinical datanews2025-10-22T14:19:51+00:00October 22nd, 2025|Endpoints News|
Takeda makes major bispecific, ADC pact with Innovent for $1.2B upfrontnews2025-10-22T07:31:10+00:00October 22nd, 2025|Endpoints News|
As China moves beyond ‘me-too,’ do Western regulators need to reconsider?news2025-10-21T16:38:56+00:00October 21st, 2025|Endpoints News|
Summit plans to take ivonescimab to FDA, even with subpar OS datanews2025-10-20T19:05:12+00:00October 20th, 2025|Endpoints News|
Roche inks $80M upfront deal for Hansoh’s cancer ADCnews2025-10-17T09:41:33+00:00October 17th, 2025|Endpoints News|
I-Mab remakes itself, with plans for Hong Kong listing, retinal R&D, and a new namenews2025-10-16T20:05:59+00:00October 16th, 2025|Endpoints News|
Pregene lands up to $1.52B deal with Kite for in vivo therapiesnews2025-10-16T19:25:26+00:00October 16th, 2025|Endpoints News|
